News

RoslinCT Welcomes Jessica Carmen as Chief Commercial Officer

RoslinCT Welcomes Jessica Carmen as Chief Commercial Officer

Jessica Carmen Joins RoslinCT as Chief Commercial Officer

RoslinCT is excited to share the news of Jessica Carmen, Ph.D., joining its esteemed leadership team as the new Chief Commercial Officer. With an impressive background spanning over two decades in business development and marketing within the cell and gene therapy sector, Dr. Carmen brings a wealth of expertise. Most recently, she held the position of Vice President of Business Development at Kincell Bio, where she significantly advanced their commercial endeavors.

Responsibilities and Impact

In her new role at RoslinCT, Dr. Carmen is set to spearhead the company’s commercial initiatives. She will oversee a diverse array of activities ranging from marketing RoslinCT's prolific technical capabilities to driving new business opportunities and nurturing essential customer relationships. Dr. Carmen will work in tandem with the integrated global leadership team, collaborating closely with operations in vital life sciences hubs.

Leadership Perspective

Geoffrey Hamilton-Fairley, Executive Chairman of RoslinCT, expressed enthusiasm about Dr. Carmen’s appointment. He emphasized, “We are thrilled to welcome Jessica to RoslinCT to attract more cell therapy developers to our sites. She brings an extensive network and a deep understanding of the manufacturing process for cell-based medicines.” This sentiment highlights the significant role Dr. Carmen is poised to play in strengthening the connections within the industry.

Dr. Carmen's Vision

Dr. Carmen herself shared her excitement about joining RoslinCT, noting, “I look forward to driving the long-term growth of this company for the therapeutic developers and the patients who rely on their ground-breaking treatments.” Her passion for advancing innovative manufacturing processes for cell therapies underscores her commitment to the vision and mission of RoslinCT.

Expertise in the Field

With an extensive professional background, Dr. Carmen is well-equipped to take on her new responsibilities. Not only did she serve as Vice President of Business Development for Kincell Bio, but she also provided consultancy support to the business development team at Oxford Biomedica. Her broad technical knowledge of cell and gene therapies further enhances her ability to contribute meaningfully to RoslinCT's goals.

Background of RoslinCT

Founded in 2006, RoslinCT has established itself as a leading global contract development and manufacturing organization (CDMO) focusing on Advanced Cell and Gene Therapies. This innovative company originated from the pivotal cloning of Dolly the Sheep at the Roslin Institute, revolutionizing the field of biotechnology. Achievements include being one of the first entities to produce clinical-grade human pluripotent stem cells.

Innovations and Milestones

In partnership with various collaborators, RoslinCT successfully developed the first-ever CRISPR-edited cell therapy product, marking a substantial leap from early development to market readiness. Equipped with 22 state-of-the-art cGMP cell therapy processing suites in Edinburgh and Hopkinton, RoslinCT offers comprehensive services, including innovative process development, clinical and commercial manufacturing, and advanced analytical development.

Commitment to Advancing Therapeutics

RoslinCT is dedicated to empowering its partners with tailored CDMO solutions that facilitate the transition from development to commercialization of life-saving cell and gene therapies worldwide. As a proud member of the GHO Capital portfolio, the organization continues to position itself at the forefront of this rapidly evolving industry.

Frequently Asked Questions

Who is Jessica Carmen?

Jessica Carmen, Ph.D., is the newly appointed Chief Commercial Officer at RoslinCT, with over 20 years of experience in the cell and gene therapy industry.

What are Dr. Carmen's responsibilities at RoslinCT?

Dr. Carmen will lead and coordinate all commercial activities, including marketing, business development, and customer relations.

What is RoslinCT known for?

RoslinCT is recognized as a leading CDMO specializing in Advanced Cell and Gene Therapies, contributing significantly to the development of human medicines.

How many facilities does RoslinCT operate?

RoslinCT operates 22 cGMP cell therapy processing suites located in Edinburgh, Scotland, and Hopkinton, Massachusetts.

What notable product did RoslinCT develop?

RoslinCT developed the first CRISPR-edited cell therapy product for a major inherited disorder, showcasing their innovative capabilities.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 65

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 108

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 29

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 65

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 53

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 164

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 40

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 125

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 115

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 59

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading

Top 5 Most Recently Viewed Articles

Synovus Appoints New Chattanooga Market Leader for Growth

Updated Category News Views 502

Synovus Appoints Jim Vaughn as Chattanooga Market Executive Synovus has recently made headlines by appointing Jim Vaughn as the new Chattanooga market executive. He brings a wealth of experience and has a solid background in the financial sector, joining from Mauldin & Jenkins, where he honed his skills over a significant tenure. Leadership Role and Responsibilities In...

Continue Reading
Navigating Recruitment Trends in Maritime and Oil & Gas for 2025

Updated Category News Views 85

Trends Shaping Recruitment in the Maritime and Oil & Gas Industries Core Group Resources stands at the forefront of talent acquisition, guiding businesses toward sustainable growth by effectively identifying and nurturing the right talent. As we approach 2025, the company has unveiled a comprehensive analysis detailing the pivotal trends that will influence recruitment...

Continue Reading
Disney and Netflix Stocks Dip Amid Warner Bros. Merger News

Updated Category News Views 430

Disney and Netflix Stocks Experience a Decline Securities of Walt Disney Co (NYSE: DIS) and Netflix Inc (NASDAQ: NFLX) are witnessing a downward trend, likely influenced by recent reports concerning a significant business maneuver involving Warner Bros. Discovery Inc (NASDAQ: WBD). Speculation arises that a coalition led by Paramount Skydance Corp (NASDAQ: PSKY) is...

Continue Reading
Alpine Income Property Trust Launches New Preferred Stock Offering

Updated Category News Views 136

Alpine Income Property Trust Announces Public Offering Alpine Income Property Trust, Inc. (NYSE: PINE) has officially announced the launch of its public offering for the Series A Cumulative Redeemable Preferred Stock, which has a liquidation preference of $25.00 per share. This initiative reflects the company’s strategic approach to expanding its capital base and...

Continue Reading
Civitas Capital Strengthens Team with New Regional Director

Updated Category News Views 127

Civitas Capital Welcomes Rishabh Gandhi Civitas Capital is thrilled to announce a significant addition to our team: Rishabh Gandhi, who joins us as Regional Director for India and the Middle East. With over nine years of invaluable experience in the EB-5 investment industry, Rishabh brings a wealth of expertise, strategic insight, and an established network of...

Continue Reading